The FDA has approved Abrilada as the second interchangeable biosimilar to adalimumab, according to a press release from Pfizer.
The approval signifies that Abrilada (adalimumab-afzb, Pfizer) can be substituted for adalimumab (Humira, Abbvie) at the pharmacy level without the intervention or required notification of the prescribing provider — at least where state law allows.
Abrilada is approved for the treatment of rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn’s disease, ulcerative colitis, plaque psoriasis and uveitis.
“With